These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28389199)

  • 21. Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States.
    Aagren M; Luo W
    J Med Econ; 2011; 14(1):108-14. PubMed ID: 21241161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthcare and associated costs related to type 2 diabetes in youth and adolescence: the TODAY clinical trial experience.
    Songer TJ; Haymond MW; Glazner JE; Klingensmith GJ; Laffel LM; Zhang P; Hirst K;
    Pediatr Diabetes; 2019 Sep; 20(6):702-711. PubMed ID: 31119838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007-2015: A registry-based cohort study.
    Jans A; Näslund I; Ottosson J; Szabo E; Näslund E; Stenberg E
    PLoS Med; 2019 Nov; 16(11):e1002985. PubMed ID: 31747392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
    Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A;
    Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resource use and costs of type 2 diabetes in Sweden - estimates from population-based register data.
    Ringborg A; Martinell M; Stålhammar J; Yin DD; Lindgren P
    Int J Clin Pract; 2008 May; 62(5):708-16. PubMed ID: 18355236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-world data in patients with type 2 diabetes.
    Paul SK; Shaw JE; Montvida O; Klein K
    Diabetes Obes Metab; 2016 Dec; 18(12):1244-1252. PubMed ID: 27502528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact and duration effect of telemonitoring on ΗbA1c, BMI and cost in insulin-treated Diabetes Mellitus patients with inadequate glycemic control: A randomized controlled study.
    Fountoulakis S; Papanastasiou L; Gryparis A; Markou A; Piaditis G
    Hormones (Athens); 2015; 14(4):632-43. PubMed ID: 26188234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
    Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
    Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs of shoulder pain and resource use in primary health care: a cost-of-illness study in Sweden.
    Virta L; Joranger P; Brox JI; Eriksson R
    BMC Musculoskelet Disord; 2012 Feb; 13():17. PubMed ID: 22325050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body mass index and use and costs of primary care services among women aged 55-79 years in England: a cohort and linked data study.
    Kent S; Jebb SA; Gray A; Green J; Reeves G; Beral V; Mihaylova B; Cairns BJ;
    Int J Obes (Lond); 2019 Sep; 43(9):1839-1848. PubMed ID: 30568274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body mass index and insulin use as identifiers of high-cost patients with type 2 diabetes: A retrospective analysis of electronic health records linked to insurance claims data.
    Johnston SS; Ammann EM; Kashyap SR; Stokes A; Hsiao CC; Daskiran M; Scamuffa R
    Diabetes Obes Metab; 2019 Jun; 21(6):1419-1428. PubMed ID: 30768824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database.
    Lage MJ; Boye KS
    Curr Med Res Opin; 2020 Sep; 36(9):1441-1447. PubMed ID: 32643451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of treatment response in patients with newly diagnosed type 2 diabetes: the Skaraborg diabetes register.
    Pikkemaat M; Melander O; Hjerpe P; Bengtsson Boström K
    J Diabetes Complications; 2017 May; 31(5):854-858. PubMed ID: 28319005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Utility of Laparoscopic Roux-en-Y Gastric Bypass in Chinese Patients with Type 2 Diabetes and Obesity with a BMI ≥ 27.5 kg/m2: a Multi-Center Study with a 4-Year Follow-Up of Surgical Cohort.
    Tu Y; Wang L; Wei L; Xu Y; Han X; Han J; Yu H; Zheng C; Bao Y; Jia W
    Obes Surg; 2019 Dec; 29(12):3978-3986. PubMed ID: 31338737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BetaMe: impact of a comprehensive digital health programme on HbA1c and weight at 12 months for people with diabetes and pre-diabetes: study protocol for a randomised controlled trial.
    Sarfati D; McLeod M; Stanley J; Signal V; Stairmand J; Krebs J; Dowell A; Leung W; Davies C; Grainger R
    Trials; 2018 Mar; 19(1):161. PubMed ID: 29506562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care.
    Counterweight Project Team
    J Health Serv Res Policy; 2008 Jul; 13(3):158-66. PubMed ID: 18573765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health-Care Costs, Glycemic Control and Nutritional Status in Malnourished Older Diabetics Treated with a Hypercaloric Diabetes-Specific Enteral Nutritional Formula.
    Sanz-Paris A; Boj-Carceller D; Lardies-Sanchez B; Perez-Fernandez L; Cruz-Jentoft AJ
    Nutrients; 2016 Mar; 8(3):153. PubMed ID: 27005661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up.
    Chen HY; Kuo S; Su PF; Wu JS; Ou HT
    Diabetes Care; 2020 Aug; 43(8):1732-1740. PubMed ID: 32444454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association between the severity of chronic kidney disease and medical costs among patients with type 2 diabetes.
    Lage MJ; Boye KS; Bae JP; Wu J; Mody R; Botros FT
    J Med Econ; 2019 May; 22(5):447-454. PubMed ID: 30736708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.